Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Lung Cancer Outlook' returned 114 results - Page 1 of 6  FEATURED RESULTS Drug Delivery in Cancer - Technologies, Markets and Companies Antibody Drug Target Atlas in Oncology Cancer Diagnostic Testing World Markets Pharmacogenetics of Breast Cancer: Towards the Individualiza... Lung Cancer, 3rd Edition   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Lung Cancer Therapeutics Market Outlook and Pipeline Analysis   Arrowhead Publishers, Nov 2009 SCLC - AstraZeneca - Eli-Lilly - GlaxoSmithKline - OSI Pharmaceuticals - Roche - Sanofi-Aventis Lung Cancer Therapeutics Market Outlook and Pipeline Analysis Global Lung Cancer Surgery Market (Devices & Treatment Outlook) – Trends & Challenges (2010 – 2015)   Markets and Markets, July 2011, Pages: 228 Strategies In Lung Cancer Surgery Market (January 2008 – March 2011) Global Lung Cancer Surgery Market (Devices & Treatment Outlook) – Trends & Challenges (2010 – 2015) Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning   Bioseeker, Aug 2009, Pages: 751 Pharmaceutical - Wilex - Wyeth - Xerion - Xoma - Yakult Honsha - YM BioSciences - Zivena Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Greater China   ICON Group International, Jan 2011, Pages: 142 .1 Disclaimers & Safe Harbor 37.2 ICON Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Greater China The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in India   ICON Group International, Jan 2011, Pages: 319 , WARRANTEES, AND USER AGREEMENT PROVISIONS 38.1 Disclaimers & Safe Harbor 38.2 ICON Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics The 2011-2016 World Outlook for Non-Small Cell Lung Cancer Therapeutics   ICON Group International, Jan 2011, Pages: 197 Harbor 8.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 World Outlook for Non-Small Cell Lung Cancer Therapeutics The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Japan   ICON Group International, Jan 2011, Pages: 141 Monetary Fund, Euromonitor, Mintel, Thomson Financial Services, the U.S. Industrial Outlook, and the World Bank). Depending on original data sources used, the definition of “non-small cell lung cancer The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Asia   ICON Group International, Jan 2011, Pages: 38 Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Asia The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Latin America   ICON Group International, Jan 2011, Pages: 35 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for non-small cell lung cancer therapeutics is not actual The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in North America & the Caribbean   ICON Group International, Jan 2011, Pages: 37 PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in North America & the Caribbean The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Oceana   ICON Group International, Jan 2011, Pages: 34 Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Oceana The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States   ICON Group International, Jan 2011, Pages: 731 PROVISIONS 11.1 Disclaimers & Safe Harbor 11.2 ICON Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Africa, Europe & the Middle East   ICON Group International, Jan 2011, Pages: 113 Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Africa, Europe & the Middle East Chinese Markets for Lung Cancer Treatment Drugs   AMID Co., Feb 2009, Pages: 189 Cancer Treatment Drugs Lung Cancer Treatment Drugs Imports and Exports Lung Cancer Drugs Imports Lung Cancer Drugs Exports Pricing Trend V.LUNG CANCER TREATMENT DRUGS MARKET OUTLOOK Lung Cancer Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries.   Markets and Markets, Nov 2011, Pages: 129 Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung Lung Cancer Therapeutics - Global Strategic Business Report   Global Industry Analysts, Inc., July 2009, Pages: 842 This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed Cancer Therapeutics - Market Insight and R&D Pipeline Analysis   Arrowhead Publishers, Aug 2008, Pages: 318 Therapy 6.6 Lung Cancer R&D Pipeline Analysis 6.6.1 Mixed Clinical Results for Avastin 6.6.2 Erbitux Improves Lung Cancer Survival 6.6.3 Zactima 6.6.4 Recentin Trial 6.7 The Outlook for Lung Cancer Cancer Biologics Pipeline: Antibodies, Peptides, and Proteins - A Competitive Review   Decision Resources, Inc., April 2011, Pages: 29 and Challenges -- Melanoma -- Non-Small-Cell Lung Cancer -- Breast Cancer 2010 and Market Outlook - Market Statistics - Market Drivers and Constraints About the Author - Abbott Laboratories - Amgen Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities   Spectra Intelligence, April 2006, Pages: 369 in the United States, 2005 Incidence and Mortality Rates by Racial Group, United States Aetiology, Pathophysiology, and Diagnosis of Cancer by Type: Europe, United Kingdom and United States Lung Cancer Aetiology The Cancer Market Outlook to 2016   Business Insights, June 2011, Pages: 164 Chemical carcinogens Age Tobacco smoke Lifestyle factors Radiation Immune system Genetics Lung cancer Overview Diagnosis, treatment, and management Epidemiology Forecast epidemiology Colorectal Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network